Stockscreener 앱 받기
74.81
0.34%
0.25
시간 외 거래:
74.79
-0.02
-0.03%
전일 마감가:
$74.56
열려 있는:
$74.68
하루 거래량:
2.42M
Relative Volume:
1.00
시가총액:
$10.16B
수익:
$105.82M
순이익/손실:
$-829.61M
주가수익비율:
-10.93
EPS:
-6.8429
순현금흐름:
$-548.92M
1주 성능:
-2.96%
1개월 성능:
+15.07%
6개월 성능:
+13.45%
1년 성능:
+132.84%
1일 변동 폭
$73.13
$75.23
1주일 범위
$72.15
$79.01
52주 변동 폭
$29.31
$80.20
Cytokinetics Inc Stock (CYTK) Company Profile
명칭
Cytokinetics Inc
전화
(650) 624-3000
주소
350 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
Compare CYTK vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CYTK
Cytokinetics Inc
|
74.81 | 10.12B | 105.82M | -829.61M | -548.92M | -6.8429 |
VRTX
Vertex Pharmaceuticals Inc
|
448.29 | 110.45B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
723.41 | 74.73B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
812.81 | 50.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
292.03 | 38.03B | 4.29B | 577.22M | 641.34M | 4.2086 |
ONC
Beone Medicines Ltd Adr
|
315.07 | 32.24B | 5.76B | 514.49M | 1.10B | 4.4813 |
Cytokinetics Inc Stock (CYTK) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-10 | 개시 | Wells Fargo | Overweight |
| 2026-01-28 | 재개 | Barclays | Overweight |
| 2025-12-18 | 업그레이드 | Goldman | Neutral → Buy |
| 2025-07-30 | 재개 | Raymond James | Mkt Perform |
| 2025-04-24 | 개시 | Barclays | Overweight |
| 2025-02-07 | 개시 | Citigroup | Buy |
| 2025-01-22 | 개시 | Stifel | Buy |
| 2024-11-08 | 개시 | RBC Capital Mkts | Outperform |
| 2024-08-13 | 다운그레이드 | Goldman | Buy → Neutral |
| 2024-01-24 | 다운그레이드 | UBS | Buy → Neutral |
| 2024-01-05 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2023-11-09 | 개시 | Goldman | Buy |
| 2023-11-07 | 개시 | B. Riley Securities | Buy |
| 2023-08-15 | 개시 | SVB Securities | Outperform |
| 2023-02-17 | 개시 | BofA Securities | Neutral |
| 2022-12-23 | 재확인 | Needham | Buy |
| 2022-12-20 | 개시 | Truist | Buy |
| 2022-10-11 | 개시 | UBS | Buy |
| 2022-01-28 | 개시 | Goldman | Buy |
| 2021-12-22 | 개시 | Oppenheimer | Outperform |
| 2021-12-10 | 개시 | JP Morgan | Overweight |
| 2021-10-07 | 개시 | Jefferies | Buy |
| 2021-03-12 | 개시 | Wolfe Research | Outperform |
| 2021-02-18 | 개시 | Barclays | Overweight |
| 2021-01-20 | 재확인 | H.C. Wainwright | Buy |
| 2020-10-29 | 개시 | Goldman | Neutral |
| 2020-07-10 | 개시 | Raymond James | Strong Buy |
| 2020-05-05 | 개시 | Mizuho | Buy |
| 2020-04-09 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2018-09-21 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-09-10 | 재개 | Morgan Stanley | Equal-Weight |
| 2017-11-22 | 재확인 | Morgan Stanley | Overweight |
| 2017-11-22 | 다운그레이드 | Needham | Strong Buy → Buy |
| 2017-11-21 | 재확인 | H.C. Wainwright | Buy |
| 2017-07-31 | 개시 | Morgan Stanley | Overweight |
| 2017-03-08 | 개시 | Rodman & Renshaw | Buy |
| 2017-02-06 | 업그레이드 | Needham | Buy → Strong Buy |
| 2016-12-16 | 개시 | Cantor Fitzgerald | Overweight |
| 2016-07-28 | 재확인 | Needham | Buy |
| 2015-11-10 | 재확인 | FBR Capital | Outperform |
| 2015-11-09 | 재확인 | ROTH Capital | Buy |
| 2015-07-24 | 재확인 | MLV & Co | Buy |
| 2014-12-31 | 재확인 | ROTH Capital | Buy |
| 2014-11-04 | 업그레이드 | MLV & Co | Hold → Buy |
| 2014-04-28 | 재확인 | Needham | Buy |
모두보기
Cytokinetics Inc 주식(CYTK)의 최신 뉴스
J.P. Morgan Maintains Cytokinetics(CYTK.US) With Buy Rating, Raises Target Price to $97 - Moomoo
Cytokinetics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference - The Manila Times
CYTK Maintained by JP Morgan -- Price Target Raised to $97.00 - GuruFocus
Growth Investors: Industry Analysts Just Upgraded Their Cytokinetics, Incorporated (NASDAQ:CYTK) Revenue Forecasts By 11% - Yahoo Finance
Analysts Are Betting On Cytokinetics, Incorporated (NASDAQ:CYTK) With A Big Upgrade This Week - 富途牛牛
Cytokinetics (CYTK) Unveils Positive MYQORZO Data at ESC 2026 Co - GuruFocus
One Bay Area company scored $800 million around its heart drug. Here's another targeting the same condition - The Business Journals
Cytokinetics completes $805 million public offering - The Pharma Letter
Cytokinetics presents new data on heart drug aficamten - Investing.com
Cytokinetics presents new data on heart drug aficamten By Investing.com - Investing.com Canada
Cytokinetics Announces New Data Related to MYQORZO® (aficamten) at ESC Heart Failure 2026 - Caledonian Record
Heart drug MYQORZO shows long-term safety as HCM burden detailed - Stock Titan
CYTK Maintains by HC Wainwright & Co. -- Price Target Raised to $140 - GuruFocus
1CYTK.MI Stock Chart | CYTOKINETICS INC (BIT:1CYTK) - ChartMill
Can Myqorzo drive growth for Cytokinetics amid competition? - MSN
Cytokinetics (NASDAQ: CYTK) prices $760.2M common stock sale at $71 - Stock Titan
Cytokinetics closes $805 million stock offering By Investing.com - Investing.com Australia
Cytokinetics closes $805 million stock offering - Investing.com
$805M raised as Cytokinetics sells 11.3M shares at $71 each - Stock Titan
Cytokinetics Announces Closing of Public Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $805 Million - marketscreener.com
Press Release: Cytokinetics Announces Closing of Public Offering of Common Stock and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $805 Million - Moomoo
CYTK SEC FilingsCytokinetics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Earnings Update: Cytokinetics, Incorporated (NASDAQ:CYTK) Just Reported And Analysts Are Boosting Their Estimates - Moomoo
CYTK Maintained by Wells Fargo -- Price Target Raised to $105 - GuruFocus
Cytokinetics, Incorporated 2026 Q1ResultsEarnings Call Presentation (NASDAQ:CYTK) 2026-05-07 - Seeking Alpha
Cytokinetics: Expect Gross Proceeds of Around $700M >CYTK - Moomoo
Cytokinetics (NASDAQ: CYTK) prices 9.859M-share offering to raise $700M - Stock Titan
B. Riley Adjusts Price Target on Cytokinetics to $146 From $108, Maintains Buy Rating - Moomoo
Jefferies raises Cytokinetics stock price target on trial results - Investing.com UK
Jefferies raises Cytokinetics stock price target on trial results By Investing.com - Investing.com Australia
Cytokinetics Is Maintained at Overweight by Wells Fargo - Moomoo
Earnings Beat: Cytokinetics, Incorporated (NASDAQ:CYTK) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts - Yahoo Finance
Cytokinetics Price Target Raised to $108.00/Share From $98.00 by Stifel - Moomoo
Why is Cytokinetics (CYTK) down 0.8% since last earnings report? - MSN
Cytokinetics Prices Upsized $700 Million Share Offering - marketscreener.com
Cytokinetics prices upsized $700M equity raise at $71 per share - MSN
Cytokinetics Announces Pricing of Upsized Public Offering of Common Stock - The Manila Times
Cytokinetics prices $700 million stock offering at $71 per share By Investing.com - Investing.com Australia
Cytokinetics prices $700 million stock offering at $71 per share - Investing.com
Cytokinetics Announces Pricing of $700 Million Public Offering of Common Stock - Quiver Quantitative
Cytokinetics prices public offering of 9.8 mln shares at $71/share - marketscreener.com
Cytokinetics prices nearly 9.9M-share sale at $71 a share - Stock Titan
Cytokinetics Offering Expected to Close May 8 >CYTK - Moomoo
CYTK Q1 Earnings Match Estimates, Revenues Beat on Myqorzo Launch - TradingView
RBC Adds Speculative Risk to Outperform Rating on Cytokinetics, Lifts Price Target to $119 From $101 - Moomoo
A Quick Look at Today's Ratings for Cytokinetics(CYTK.US), With a Forecast Between $101 to $136 - Moomoo
Cytokinetics' Rapid Growth of Myqorzo not Fully Priced in by Investors, RBC Says - marketscreener.com
Cytokinetics rallies on late-stage Myqorzo data, strengthening sales outlook - S&P Global
FMR LLC increases stake in Cytokinetics (NASDAQ: CYTK) to 9.0% - Stock Titan
Truist raises Cytokinetics stock price target on positive trial data By Investing.com - Investing.com South Africa
Cytokinetics Stock Rallies After Pivotal Heart Disease Study Hits Dual Primary Endpoints - Sahm
Cytokinetics Inc (CYTK) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.74%
자본화:
|
볼륨(24시간):